[{"data":1,"prerenderedAt":271},["ShallowReactive",2],{"$f9c6zsa4xg0xl":3},{"schema":4,"slug":5,"series":6,"series_slug":7,"name":8,"year":9,"therapeutic_area":10,"generated_at":11,"counts":12,"top_targets":23,"top_modalities":59,"top_diseases":87,"top_companies":115,"key_results":147,"trends":237,"previous_editions":246,"comparison":250,"highlighted_classes":266},1,"asco-2026","ASCO","asco","ASCO Annual Meeting 2026",2026,"Oncology","2026-11-05T22:19:09Z",{"abstracts":13,"drug_linked":14,"companies":15,"by_phase":16},7281,2794,532,{"Phase 1":17,"Phase 1\u002F2":18,"Phase 2":19,"Phase 4":20,"Phase 2\u002F3":21,"Phase 3":22},330,210,643,5,37,389,[24,28,32,35,38,42,45,48,52,56],{"name":25,"count":26,"share":27},"PDCD1",442,16,{"name":29,"count":30,"share":31},"ERBB2",155,6,{"name":33,"count":34,"share":31},"CD274",154,{"name":36,"count":37,"share":20},"EGFR",141,{"name":39,"count":40,"share":41},"TUBB",105,4,{"name":43,"count":44,"share":41},"VEGFR2",104,{"name":46,"count":47,"share":41},"CD3",99,{"name":49,"count":50,"share":51},"VEGFR4",87,3,{"name":53,"count":54,"share":55},"VEGFR-1",61,2,{"name":57,"count":58,"share":55},"TS",60,[60,64,67,71,75,78,81,84],{"name":61,"count":62,"share":63},"Small molecules",1526,55,{"name":65,"count":66,"share":21},"Monoclonal antibodies",1026,{"name":68,"count":69,"share":70},"Antibody-drug conjugates",301,11,{"name":72,"count":73,"share":74},"Bispecific antibodies",223,8,{"name":76,"count":77,"share":41},"Cell therapies",110,{"name":79,"count":80,"share":41},"Radiopharmaceuticals",103,{"name":82,"count":83,"share":51},"Non-antibody therapeutic proteins",95,{"name":85,"count":86,"share":55},"Peptides",69,[88,91,94,97,100,103,105,108,110,112],{"name":89,"count":90,"share":70},"non-small cell lung cancer (NSCLC)",315,{"name":92,"count":93,"share":70},"breast cancer",307,{"name":95,"count":96,"share":20},"colorectal cancer (CRC)",148,{"name":98,"count":99,"share":41},"melanoma",115,{"name":101,"count":102,"share":41},"prostate cancer (PCa)",107,{"name":104,"count":44,"share":41},"gastric cancer (GC)",{"name":106,"count":107,"share":41},"triple-negative breast cancer (TNBC)",101,{"name":109,"count":83,"share":51},"head and neck squamous cell carcinoma (HNSCC)",{"name":111,"count":83,"share":51},"ovarian cancer",{"name":113,"count":114,"share":51},"hepatocellular carcinoma (HCC)",94,[116,120,123,126,129,132,135,138,141,144],{"name":117,"count":118,"share":119},"Merck",200,7,{"name":121,"count":122,"share":20},"Bristol Myers Squibb",153,{"name":124,"count":125,"share":20},"AstraZeneca",138,{"name":127,"count":128,"share":41},"Pfizer",108,{"name":130,"count":131,"share":41},"Genentech",106,{"name":133,"count":134,"share":51},"Eli Lilly",78,{"name":136,"count":137,"share":51},"Novartis",76,{"name":139,"count":140,"share":55},"Daiichi Sankyo",66,{"name":142,"count":143,"share":55},"Amgen",65,{"name":145,"count":146,"share":55},"BeiGene",58,[148,157,165,172,179,187,195,203,210,217,224,231],{"title":149,"drug":150,"company":152,"phase":153,"disease":154,"finding":155,"url":156},"RINGSIDE: A phase 3 randomized, placebo-controlled trial of varegacestat for treatment of progressing desmoid tumors.",{"name":151,"slug":151},"varegacestat","Immunome","Phase 3","aggressive fibromatosis (AF)","VAR demonstrated significantly better PFS compared with PBO (hazard ratio [HR]: 0.16 [95% CI: 0.07, 0.38; P \u003C0.0001]).","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.16_suppl.11506",{"title":158,"drug":159,"company":161,"phase":153,"disease":162,"finding":163,"url":164},"MajesTEC-9: A phase 3 randomized study of teclistamab monotherapy vs investigator’s choice of pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone (PVd\u002FKd) in patients (pts) with relapsed refractory multiple myeloma (RRMM).",{"name":160,"slug":160},"teclistamab",null,"multiple myeloma (MM)","With 17.3-mo median follow-up, Tec significantly improved PFS vs PVd\u002FKd (HR, 0.29; 95% CI, 0.23–0.38; P \u003C0.0001); mPFS: NR vs 8.2 mo; 18-mo PFS rate: 69.8% vs 26.9%.","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.16_suppl.7507",{"title":166,"drug":167,"company":161,"phase":153,"disease":106,"finding":170,"url":171},"Izalontamab brengitecan (iza-bren) versus physician’s choice of chemotherapy in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC): A randomized phase III study.",{"name":168,"slug":169},"izalontamab brengitecan","izalontamab-brengitecan","The confirmed objective response rate (cORR) assessed by BICR was 51.7% with iza-bren and 20.5% with TPC (odds ratio, 4.28 [95% CI, 2.75-6.66]).","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.17_suppl.lba1003",{"title":173,"drug":174,"company":176,"phase":153,"disease":92,"finding":177,"url":178},"A randomized, open-label, phase 3 study of gedatolisib + fulvestrant ± palbociclib vs standard of care in HR+\u002FHER2−\u002F PIK3CA -mutant (MT) advanced breast cancer (VIKTORIA-1 Study 2).",{"name":175,"slug":175},"gedatolisib","Celcuity","Median PFS for the geda doublet (n=52) vs alpelisib\u002Ffulv was 11.3 vs. 5.6 mos (HR, 0.51; 95% CI, 0.33-0.79; P\u003C0.0013).","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.17_suppl.lba1008",{"title":180,"drug":181,"company":161,"phase":153,"disease":184,"finding":185,"url":186},"Randomized, double-blind phase 3 trial of the fixed-dose combination fosrolapitant\u002Fpalonosetron (HR20013) plus dexamethasone for prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.",{"name":182,"slug":161,"named_as":183},"rolapitant + palonosetron","HR20013","chemotherapy-induced nausea and vomiting (CINV)","Time to treatment failure analysis favored HR20013 (HR 0.52, 95% CI 0.40–0.69).","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.16_suppl.11006",{"title":188,"drug":189,"company":191,"phase":153,"disease":192,"finding":193,"url":194},"Primary results of the phase 3 peak study of bezuclastinib + sunitinib vs sunitinib monotherapy in advanced gastrointestinal stromal tumors (GIST).",{"name":190,"slug":190},"bezuclastinib","Cogent Biosciences","gastrointestinal stromal tumor (GIST)","ORR significantly improved with the combination vs monotherapy (46% vs 26%; risk difference, 20%; 95% CI, 10.6-28.6; P\u003C0.0001).","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.16_suppl.11500",{"title":196,"drug":197,"company":199,"phase":153,"disease":200,"finding":201,"url":202},"Luvometinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: A randomized, double-blind, placebo-controlled, phase 3 trial.",{"name":198,"slug":198},"luvometinib","Fosun Pharma","neurofibromatosis type 1 (NF1)","The median DOR was 15.1 months (95% CI, 14.8-NE), with a 85.2% rate of DOR ≥12 months with luvometinib.","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.16_suppl.3017",{"title":204,"drug":205,"company":207,"phase":153,"disease":104,"finding":208,"url":209},"Neoadjuvant\u002Fadjuvant serplulimab vs. placebo combined with chemotherapy for PD-L1–positive gastric cancer: A randomized, double-blind, multicenter phase 3 study.",{"name":206,"slug":206},"serplulimab","Henlius","Pathological complete response rate was higher in the serplulimab group than in the placebo group (21.6% vs 6.4%; odds ratio 3.95).","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.16_suppl.4009",{"title":211,"drug":212,"company":161,"phase":153,"disease":89,"finding":215,"url":216},"Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus pembrolizumab (P) as first-line treatment for PD-L1–positive advanced non-small cell lung cancer (NSCLC): Results from the randomized phase 3 OptiTROP-Lung05 study.",{"name":213,"slug":214},"sacituzumab tirumotecan","sacituzumab-tirumotecan","PFS by BICR was significantly longer in the sac-TMT + P group than the P group (median, not reached vs 5.7 months; HR, 0.35; 95% CI, 0.26-0.47; p \u003C 0.0001).","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.16_suppl.8506",{"title":218,"drug":219,"company":161,"phase":153,"disease":221,"finding":222,"url":223},"SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma.",{"name":220,"slug":220},"abemaciclib","Liposarcoma","Abemaciclib demonstrated a statistically significant improvement in PFS at 9.67m vs placebo at 1.52m (hazard ratio [HR] 0.39; 95% confidence interval [CI], 0.25–0.59; p \u003C 0.001).","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.17_suppl.lba2",{"title":225,"drug":226,"company":161,"phase":153,"disease":228,"finding":229,"url":230},"Node-sparing modified short-course radiotherapy combined with CAPOX and tislelizumab versus conventional short-course preoperative chemoradiotherapy for proficient mismatch repair or microsatellite stable locally advanced rectal cancer (mRCAT-III): A multicenter, randomized, open-label, phase 3 trial.",{"name":227,"slug":227},"tislelizumab","rectal cancer","In the ITT population, the experimental group demonstrated a significantly superior pCR rate compared to the Control group: 61.4% (47\u002F77) vs 28.6% (22\u002F77) (P \u003C 0.001).","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.17_suppl.lba3515",{"title":232,"drug":233,"company":127,"phase":153,"disease":101,"finding":235,"url":236},"TALAPRO-3: Talazoparib (TALA) + enzalutamide (ENZA) compared with placebo (PBO) + ENZA for the treatment of patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) harboring homologous recombination repair (HRR) gene alterations.",{"name":234,"slug":234},"talazoparib","Interim analysis of OS favored TALA + ENZA but has not reached statistical significance (74 deaths TALA + ENZA, 91 deaths PBO + ENZA; HR, 0.767; 95% CI, 0.564–1.044).","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2026.44.17_suppl.lba5007",{"summary":238,"bullets":240},[239],"Small molecules, the most frequent modality, accounted for 55% of drug-linked abstracts, up from 44% in 2025. Monoclonal antibodies accounted for 37% of drug-linked abstracts, up from 29% in 2025. Peptides (2%) were new to the top modalities compared with 2025.",[241,242,243,244,245],"TS (2% of drug-linked abstracts) was new to the top targets compared with 2025.","PDCD1 was the most frequent target (16%).","Non-small cell lung cancer (NSCLC) was the most frequent disease (11%).","Merck had the largest company share (7%).","Bispecific antibodies accounted for 8% of drug-linked abstracts, up from 6% in 2025.",[247],{"year":248,"abstracts":249},2025,6599,{"previous_year":248,"abstracts":251,"targets":254,"modalities":255,"new_in_top_targets":264,"new_in_top_modalities":265},{"previous":249,"current":13,"change_pct":252,"direction":253},10,"rose",[],[256,259,262],{"name":61,"count":62,"share":63,"previous_count":257,"previous_share":258,"direction":253},1117,44,{"name":65,"count":66,"share":21,"previous_count":260,"previous_share":261,"direction":253},748,29,{"name":72,"count":73,"share":74,"previous_count":263,"previous_share":31,"direction":253},149,[57],[85],[267,270],{"name":68,"count":69,"share":70,"previous_count":268,"previous_share":252,"direction":269},258,"flat",{"name":72,"count":73,"share":74,"previous_count":263,"previous_share":31,"direction":253},1793970603091]